Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H27NO.ClH |
Molecular Weight | 321.885 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H]1[C@H]2CC3=CC=C(O)C=C3[C@]1(C)CCN2CC=C(C)C
InChI
InChIKey=OQGYMIIFOSJQSF-DTOXXUQYSA-N
InChI=1S/C19H27NO.ClH/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19;/h5-7,12,14,18,21H,8-11H2,1-4H3;1H/t14-,18+,19+;/m0./s1
Molecular Formula | C19H27NO |
Molecular Weight | 285.4238 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.drugs.com/cdi/pentazocine.html | https://www.ncbi.nlm.nih.gov/pubmed/23370666Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12379919 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016194s079s080lbl.pdf | https://www.drugbank.ca/drugs/DB00652
Sources: https://www.drugs.com/cdi/pentazocine.html | https://www.ncbi.nlm.nih.gov/pubmed/23370666
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/12379919 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/016194s079s080lbl.pdf | https://www.drugbank.ca/drugs/DB00652
Pentazocine is a synthetically prepared prototypical mixed agonist-antagonist narcotic (opioid analgesic) drug of the benzomorphan class of opioids used to treat moderate to moderately severe pain. Pentazocine is sold under several brand names, such as Fortral, Sosegon, Talwin NX. Pentazocine acts as an agonist of κ-opioid receptors and as an antagonist of μ-opioid receptors. This compound may exist as one of two enantiomers, named (+)-pentazocine and (−)-pentazocine. Side effects are similar to those of morphine, but pentazocine, due to its action at the kappa opioid receptor is more likely to invoke psychotomimetic effects. High dose may cause high blood pressure or high heart rate.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2831363 |
6.9 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2831363 |
75.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TALWIN Approved UsePentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for the relief of moderate to severe pain. Pentazocine Hydrochloride and Naloxone Hydrochloride Tablets, USP is indicated for oral use only. Launch Date-7.7068796E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
227 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
102 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1311 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
536 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
80 mg single, intramuscular dose: 80 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
4.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3709032/ |
40 mg single, intramuscular dose: 40 mg route of administration: Intramuscular experiment type: SINGLE co-administered: |
PENTAZOCINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Respiratory depression, Hypotension... AEs leading to discontinuation/dose reduction: Respiratory depression Sources: Hypotension (severe) |
30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Co-administed with:: benzodiazepines Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Sedation, Coma... AEs leading to discontinuation/dose reduction: Sedation Sources: Coma |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Respiratory depression | Disc. AE | 30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypotension | severe Disc. AE |
30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Coma | Disc. AE | 30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Co-administed with:: benzodiazepines Sources: |
unhealthy Health Status: unhealthy Sources: |
Sedation | Disc. AE | 30 mg single, intramuscular Dose: 30 mg Route: intramuscular Route: single Dose: 30 mg Co-administed with:: benzodiazepines Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/17823102/ Page: 6.0 |
likely | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/17823102/ Page: 6.0 |
likely | |||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19279232/ Page: 3.0 |
||||
PubMed
Title | Date | PubMed |
---|---|---|
Mental and emotional disturbance with pentazocine (Talwin) use. | 1975 Jul |
|
Pentazocine addict nephropathy: a case report. | 1992 Mar |
|
Effect of drugs influencing central serotonergic mechanisms on pentazocine-induced catalepsy in mice. | 1998 Dec |
|
Phencyclidine impairs latent learning in mice: interaction between glutamatergic systems and sigma(1) receptors. | 2001 Apr |
|
Molecular cloning and pharmacological characterization of the rat sigma1 receptor. | 2001 Aug 1 |
|
[Analysis of prehospital analgesia administered to victims with traumatic injuries]. | 2001 Jul-Aug |
|
[Influence of intubation maneuver with or without premedication for intracranial hemorrhage with unconsciousness]. | 2001 Mar |
|
Chitosan based pentazocine microspheres for intranasal systemic delivery: development and biopharmaceutical evaluation. | 2001 Mar |
|
Some of the effects of the selective sigma ligand (+)pentazocine are mediated via a naloxone-sensitive receptor. | 2001 Mar 15 |
|
A multireceptorial binding reinvestigation on an extended class of sigma ligands: N-[omega-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites. | 2001 May |
|
Experience with urine drug testing by the Correctional Service of Canada. | 2001 Sep 15 |
|
Sigma(2)-receptor regulation of dopamine transporter via activation of protein kinase C. | 2002 Apr |
|
[The effect of ketamine on reducing postoperative agitation after sevoflurane anesthesia in pediatric strabismus surgery]. | 2002 Dec |
|
Pharmacological treatment of postoperative shivering: a quantitative systematic review of randomized controlled trials. | 2002 Feb |
|
Binding of sigma receptor ligands and their effects on muscarine-induced Ca(2+) changes in SH-SY5Y cells. | 2002 Feb 1 |
|
Renal amyloidosis in a pentazocine addict. | 2002 Jul |
|
Fibromyositis after intramuscular pentazocine abuse. | 2002 Jul-Sep |
|
Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)-N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the sigma(1) receptor. | 2002 Jun 6 |
|
Sigma1 receptor modulation of opioid analgesia in the mouse. | 2002 Mar |
|
Synthesis and evaluation of [18F]fluoroethyl SA4503 as a PET ligand for the sigma receptor. | 2002 Mar 15 |
|
[Perioperative management for nephrectomy using combined spinal-epidural anesthesia with sedation in a patient with cerebral palsy under maintenance hemodialysis]. | 2002 Nov |
|
Investigation on the influx transport mechanism of pentazocine at the blood-brain barrier in rats using the carotid injection technique. | 2002 Oct |
|
Myocardial protection by anesthetic agents against ischemia-reperfusion injury: an update for anesthesiologists. | 2002 Oct |
|
Demographics, assessment and management of pain in the elderly. | 2003 |
|
Agonist/antagonist properties of nalbuphine, butorphanol and (-)-pentazocine in male vs. female rats. | 2003 Apr |
|
Permanently oriented antibody immobilization for digoxin determination with a flow-through fluoroimmunosensor. | 2003 Apr |
|
Postoperative pain management following caesarean section in University of Ilorin Teaching Hospital (UITH), Ilorin, Nigeria. | 2003 Dec |
|
Enhanced sensitivity to the antinociceptive effects of kappa opioids in naltrexone-treated rats: dose- and time-dependent effects. | 2003 Dec |
|
Sex differences in (-)-pentazocine antinociception: comparison to morphine and spiradoline in four rat strains using a thermal nociceptive assay. | 2003 Feb |
|
Opioid prescription for terminally ill outpatients in a district of northern Italy: a retrospective survey. | 2003 Jul |
|
Migratory hydroamination: a facile enantioselective synthesis of benzomorphans. | 2003 Jul 23 |
|
Analgesic activity of Piper longum Linn. root. | 2003 Jun |
|
Modulation of Fas receptor proteins and dynamin during opiate addiction and induction of opiate withdrawal in rat brain. | 2003 Nov |
|
Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. | 2003 Oct |
|
[Combined use of intrathecal morphine and diclofenac suppository for postoperative analgesia after caesarean section]. | 2003 Oct |
|
Procaine hydrochloride fails to relieve pain in patients with acute pancreatitis. | 2004 |
|
Pentazocine-induced cutaneous sclerosis and panniculitis in an Indian male. | 2004 Jul |
|
Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. | 2004 Jun |
|
Intrathecal morphine, but not buprenorphine or pentazocine, can induce spastic paraparesis after a noninjurious interval of spinal cord ischemia in the rat. | 2004 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/cdi/pentazocine.html
Initial dose: 30 mg by intramuscular, subcutaneous, or intravenous route. This may be repeated every 3 to 4 hours.
Doses in excess of 30 mg intravenously or 60 mg intramuscularly or subcutaneously are not recommended.
Maximum daily dose: 360 mg
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23370666
Cultured bovine adrenal medullary cells (1 × 10^6 / well) or SK-N-SH cells (0.3 × 10^6 / well) were preincubated with or without PTZ (Pentazocine) for the indicated times and further incubated at 37°C for another 12 min in KRH buffer containing 100 μM pargyline, 1 mM ascorbic acid, and [3H]NE (500 or 100 nM, respectively, 0.1 μCi) in the presence or absence of desipramine and PTZ. KRH buffer was composed of 154 mM NaCl, 5.6 mM KCl, 1.1 mM MgSO4, 2.2 mM CaCl2, 10 mM HEPES-Tris, and 10 mM glucose, adjusted to pH 7.4. After incubation, the cells were rapidly washed three times with 250 μl of ice-cold KRH buffer and solubilized in 500 μl of 10% Triton X-100. The radioactivity in the solubilized cells was counted with a liquid scintillation counter.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 18:55:22 UTC 2022
by
admin
on
Fri Dec 16 18:55:22 UTC 2022
|
Record UNII |
A36BXO4PPX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
9709
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB03685MIG
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
104973
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | RxNorm | ||
|
2276-52-0
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
218-896-9
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
ALTERNATIVE | |||
|
441277
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
A36BXO4PPX
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
M8503
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | Merck Index | ||
|
C47661
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
A36BXO4PPX
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
DTXSID00915701
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
64024-15-3
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
DBSALT001009
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
264-612-1
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY | |||
|
CHEMBL560
Created by
admin on Fri Dec 16 18:55:22 UTC 2022 , Edited by admin on Fri Dec 16 18:55:22 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |